dc.contributor.author | Durak, Evin Aycicek | |
dc.contributor.author | MESUT, Burcu | |
dc.contributor.author | Özsoy, Yıldız | |
dc.contributor.author | CEVHER, Erdal | |
dc.contributor.author | Kurtgöz, İbrahim | |
dc.date.accessioned | 2021-12-10T11:59:16Z | |
dc.date.available | 2021-12-10T11:59:16Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Durak E. A. , Kurtgöz İ., MESUT B., CEVHER E., Özsoy Y., "Stability indicating method development and validation of ranolazine extended release tablets", Acta Pharmaceutica Sciencia, cilt.59, sa.3, ss.419-434, 2021 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_a1813a78-e70e-4be4-9fc5-62df157a4bc5 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/173027 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/a1813a78-e70e-4be4-9fc5-62df157a4bc5/file | |
dc.identifier.uri | https://doi.org/10.23893/1307-2080.aps.05925 | |
dc.description.abstract | © 2021, Istanbul Medipol University. All rights reserved.The objective of this study was to develop and validate the stability-indicating method for newly developed Extended-Release tablet formulation of Ranolazine. First, new Ranola-zine tablet formulation was developed. These tablets were analyzed by using a High-Per-formance Liquid Chromatography system with a UV detector at 220 nm wavelength and by using C8-3 column (150 mm x 4.6 mm i.d; 5 µm particle size). The injection volume of the system was 10 µl. The validation parameters; Selectivity, linearity, accuracy, robust-ness, precision and limit of quantification and detection parameters were proved good re-sults. A highly sensitive and simple HPLC-UV analytical method of the Ranolazine tablet formulation was developed in accordance with ICH Guideline Q2 and Q3. | |
dc.language.iso | eng | |
dc.subject | Klinik Tıp | |
dc.subject | TROPİKAL TIP | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Pharmaceutical Science | |
dc.subject | Life Sciences | |
dc.subject | Sağlık Bilimleri | |
dc.title | Stability indicating method development and validation of ranolazine extended release tablets | |
dc.type | Makale | |
dc.relation.journal | Acta Pharmaceutica Sciencia | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 59 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 419 | |
dc.identifier.endpage | 434 | |
dc.contributor.firstauthorID | 2721319 | |